Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers

International Journal of Obesity volume 24, pages 187–194 (2000)Cite this article

Abstract

OBJECTIVES: After 10 d of orlistat administration (120 mg three times/day), the primary objective was to determine the drug's effect on postprandial plasma lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) activities on day 10 after an oral fat-load. The secondary objectives were to determine the effects of orlistat on 12 h postprandial measures of: (1) preheparin HTGL and LPL; and (2) serum triglycerides, very-low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and free fatty acids.

METHODS: Twenty-four normal-weight, healthy male volunteers were randomized to either 120 mg orlistat (n=12) or placebo (n=12) three times a day with meals for 10 d. Preheparin LPL and HTGL activities and LPL specific activity were measured in the fasted state on days 1, 5, and 10. On days 5 and 10 the study medication (orlistat or placebo) was taken at the beginning of a fat-rich breakfast and serum lipid and lipoprotein levels monitored for 12 h postprandially. On day 10, 15 min postheparin HTGL activity was measured 8 h after the fat-rich breakfast.

RESULTS: No differences were found between groups in fasting levels of preheparin LPL or HTGL activity or in LPL-specific activity on days 1, 5 and 10. No difference was found between the two treatment groups in postheparin HTGL activity 8 h after the fat-rich breakfast. Also, no differences were found between the two groups in plasma triglycerides or lipoproteins.

CONCLUSION: The results indicate that the oral administration of orlistat (120 mg t.i.d.) does not significantly alter plasma triglycerides or lipoproteins, and that the inhibitory effect of orlistat on lipases is limited to the gastrointestinal tract and is not manifested systemically.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Blum-Kaelin D, Hill H . Effect of tetrahydrolipstatin (RO 180647/002, THL) on rat, dog and human post-heparin plasma lipolytic activity in vitro Hoffman-LaRoche GCR 1990 B-103: 367.

    Google Scholar 

  2. Kamm JJ . Oncogenicity (feeding) study with RO 180647 in the rat Hoffmann-LaRoche GCR 1996 N-138: 885.

    Google Scholar 

  3. Eckel RH, Goldberg IJ, Steiner L, Yost TJ, Paterniti JR Jr . Plasma lipolytic activity. Relationship to postheparin lipolytic activity and evidence for metabolic regulation Diabetes 1988 37: 610–615.

    Article  CAS  Google Scholar 

  4. Van Gaal LF, Broom JI, Enzi G, Toplak H . Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month dose-ranging study. Orlistat dose-ranging study group Eur J Clin Pharmacol 1999 54: 125–132.

    Article  Google Scholar 

  5. Glaser DS, Yost TJ, Eckel RH . Preheparin lipoprotein lipolytic activities: Relationship to plasm lipoproteins and postheparin lipolytic activities J Lipid Res 1992 33: 209–214.

    CAS  PubMed  Google Scholar 

  6. Goers JW, Pedersen ME, Kern PA, Ong J, Schotz MC . An enzyme-linked immunoassay for lipoprotein lipase Anal Biochem 1987 166: 27–35.

    Article  CAS  Google Scholar 

  7. Van Gent CM, van der Voort HA, de Bruyn AM, Klein F . Cholesterol determinations. A comparative study of methods with special reference to enzymatic procedures Clin Chim Acta 1977 75: 243–251.

    Article  CAS  Google Scholar 

  8. Wu LL, Warnick GR, Wu JT, Williams RR, Lalouel J . A rapid micro-scale procedure for determination of the total lipid profile Clin Chem 1989 35: 1486–1491.

    CAS  PubMed  Google Scholar 

  9. Kohlmeier M . Direct enzymic measurement of glycerides in serum and in lipoprotein fractions Clin Chem 1986 32: 63–66.

    CAS  PubMed  Google Scholar 

  10. Demacker PNM, Hijmans AGM, Jansen AP . Enzymatic extraction determinations of free fatty acids in serum compared Clin Chem 1982 28: 1765–1768.

    CAS  PubMed  Google Scholar 

  11. Fernandez M, Borgstrom B . Effects of tetrahydrolipstatin, a lipase inhibitor, on absorption of fat from the intestine of the rat Biochim Biophys Acta 1989 1001: 249–255.

    Article  CAS  Google Scholar 

  12. Zhi J, Melia AT, Eggers H, Joly R, Patel IH . Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers J Clin Pharmacol 1995 35: 1103–1108.

    Article  CAS  Google Scholar 

  13. Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K, Strobel W, Sjostrom L, van der Veen EA . Orlistat (RO 19-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study Int J Obes 1995 19: 221–226.

    CAS  Google Scholar 

  14. Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW . Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor Metabolism 1994 43: 293–298.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Metabolism and Diabetes, University of Colorado Health Sciences Center, 4200 E. 9th Avenue, Denver, 80262, CO

    TY Shepard, DR Jensen & RH Eckel

  2. Hoffmann-LaRoche Inc., 340 Kingsland Street, Nutley, 07110-1199, NJ, USA

    S Blotner, J Zhi, R Guerciolini & D Pace

Authors
  1. TY Shepard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. DR Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Blotner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Zhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Guerciolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Pace
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. RH Eckel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to RH Eckel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shepard, T., Jensen, D., Blotner, S. et al. Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers. Int J Obes 24, 187–194 (2000). https://doi.org/10.1038/sj.ijo.0801105

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0801105

Keywords

Search

Advanced search

Quick links